A. Lee

发表

Detection of insulin and insulin-like growth factors I and II in saliva and potential synthesis in the salivary glands of mice. Effects of type 1 diabetes mellitus.

H. Yamamoto, M. Humphreys-Beher, K. Purushotham, 1995, Biochemical pharmacology.

Developmental and hormonal signals dramatically alter the localization and abundance of insulin receptor substrate proteins in the mammary gland.

C. Kahn, S. Oesterreich, J. Rosen, 2003, Endocrinology.

Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.

S. Hilsenbeck, C. Osborne, D. Yee, 1999, Molecular endocrinology.

Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer

E. Sokol, Piyush B. Gupta, G. Frampton, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer

Adrian V. Lee, P. O’Connell, C. Osborne, 2001, British Journal of Cancer.

FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling

A E Giuliano, A. Giuliano, P. Ray, 2012, Oncogene.

Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop.

D. Yee, J. Jackson, J. Figueroa, 1995, The Journal of clinical endocrinology and metabolism.

Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells.

D. Yee, J. Gooch, Adrian V. Lee, 1998, Cancer Research.

Genetic manipulation of the IGF-I axis to regulate mammary gland development and function.

D. Hadsell, A. V. Lee, S. Bonnette, 2002, Journal of dairy science.

Role of the IGF System in Breast Cancer Proliferation and Progression

D. Yee, A. V. Lee, A. Lee, 1999 .

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer

Adrian V. Lee, B. Leyland-Jones, M. Rosenzweig, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Recurrent hyperactive ESR 1 fusion proteins in endocrine therapy-resistant breast cancer

B. Leyland-Jones, P. Lucas, G. Frampton, 2018 .

Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.

Adrian V. Lee, S. Oesterreich, X. Cui, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Activation of renal signaling pathways in db/db mice with type 2 diabetes.

H. Abboud, D. Féliers, B. Kasinath, 2001, Kidney international.

Rapid induction of IGF-IR signaling in normal and tumor tissue following intravenous injection of IGF-I in mice.

M. Fiorotto, J. Mills, D. Hadsell, 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Inhibition of oestrogen receptor activity by the co-repressor HET/SAF-B is relieved by blockade of histone deacetylase activity.

S. Oesterreich, Q. Zhang, A. Lee, 2000, European journal of cancer.

HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer.

C. Osborne, G. Clark, S. Oesterreich, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.

C. Osborne, M. Michaelis, J. Davie, 2000, Molecular endocrinology.

Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement.

A. Buzdar, J. Ingle, P. Goss, 2001, Clinical Cancer Research.

A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone.

P. Brown, S. McGuire, B. O’Malley, 2012, Molecular endocrinology.

Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival.

S. Hilsenbeck, D. Yee, S. Hilsenbeck, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth.

C. Osborne, S. Oesterreich, W. Welshons, 2001, Cancer research.

Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats.

F. Talamantes, R. Guzman, S. Nandi, 2001, Carcinogenesis.

Insulin-like growth factors and breast cancer.

D. Yee, A. Lee, A. Lee, 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells.

D. Yee, J. Jackson, C. Weng, 1997, The Journal of endocrinology.

Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features.

S. Hilsenbeck, D. Yee, J. Jackson, 1996, Journal of the National Cancer Institute.

Inability of overexpressed des(1-3)human insulin-like growth factor I (IGF-I) to inhibit forced mammary gland involution is associated with decreased expression of IGF signaling molecules.

Y. Klimentidis, D. Hadsell, D. Torres, 2001, Endocrinology.

Review of: Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signalling pathways but not modulation of progesterone receptor activity

A. V. Lee, A. Lee, 2005 .

A. Lee, 2005 .

Lac repressor inducible gene expression in human breast cancer cells in vitro and in a xenograft tumor.

S. McGuire, D. Yee, D. Wolf, 1997, BioTechniques.